All In Biotech

NDA 020222 · Pfizer

Colestid

Colestipol Hydrochloride · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: May 25, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Jul 19, 1994

Approved uses

1

Original approval plus efficacy supplements

Registered trials

7

3 Phase 3, 0 recruiting

FAERS reports

2,659

1,527 serious, 115 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 13, 2025.

INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 19, 1994 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • COLESTID · COLESTIPOL HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Colestipol" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea380
  • off label use288
  • nausea233
  • fatigue220
  • drug ineffective181
  • headache145
  • vomiting128
  • pain127
  • weight decreased116
  • arthralgia115
  • asthenia115
  • dizziness112

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200425
200532
200624
200735
200840
200968
2010100
2011102
2012130
201356
201453
201586
2016113
2017123
2018155
2019150
2020128
2021163
2022213
2023210
2024236
2025245
2026172

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Colestid (Colestipol HCl)

2024 spending

$41K

Beneficiaries

95

200 claims

Per beneficiary

$429

$2.02 per unit

View as table
YearSpending
2020$301,136
2021$353,580
2022$135,142
2023$199,073
2024$40,759

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 128 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.